Emma Andrus

4 days ago | dermatologytimes.com | Emma Andrus |Adam Friedman

In a recent interview with Dermatology Times, Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, shared insights from a new study examining how US dermatologists screen for and manage lichen planus.1 The cross-sectional study, published in Dermatology and Therapy,2 surveyed more than 400 dermatologists and uncovered wide variation in clinical practices, especially regarding screening for comorbidities and...

4 days ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Dermatology Times has compiled a list of dermatological meetings taking place during the month of June. Discover essential business metrics for PAs in dermatology, empowering practice ownership and driving sustainable growth through data-driven strategies. Recludix advances REX-8756, a first-in-class oral STAT6 inhibitor, showing promise for safer, targeted treatment of type 2 inflammatory skin diseases.

5 days ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Pelage Pharmaceuticals recently announced its novel topical agent, PP405, has advanced to a phase 2a study for androgenetic alopecia, with enrollment currently underway at sites across the US. Dermatology Times recently spoke with Qing Yu Christina Weng, MD, chief medical officer of Pelage.

5 days ago | dermatologytimes.com | Emma Andrus

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

5 days ago | dermatologytimes.com | Emma Andrus

Recludix Pharma announced today the nomination of its lead development candidate, REX-8756, an oral, reversible, and highly selective STAT6 inhibitor designed to address a wide range of type 2 inflammatory diseases, including atopic dermatitis.1The announcement coincides with the completion of Good Laboratory Practice (GLP) toxicology studies for the candidate, a milestone that initiated a $50 million payment under the company’s collaboration with Sanofi.